Vaxcyte, Inc.

Biotechnology company · San Carlos, California, United States · Nasdaq: PCVX

Vaxcyte, Inc. is a biotechnology company headquartered in San Carlos, California, United States. Its earliest recorded incorporation is in 2013. Its shares trade on Nasdaq under the ticker PCVX. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $196,063 in total, most recently in 2016. It has reported private securities offerings to the US SEC, most recently $110 million sold in a notice filed in 2020.

www.sutrovax.comProfile compiled from public records. Is this your company? Request a correction or update

Vaxcyte at a glance

Typebiotechnology company
HeadquartersSan Carlos, California, United States
Earliest incorporation on record2013
Stock listingNasdaq: PCVX
SEC industryBiological Products, (No Diagnostic Substances)
Employees (per SBIR records)10
SEC CIK1649094

What does Vaxcyte do?

US government research funding

1 SBIR/STTR small-business research award from US health agencies, $196,063 in total (2016). NIH funding came from the National Institute of Allergy and Infectious Diseases.

Private fundraising reported to the SEC

4 Form D notices; the most recent reported $110 million sold (2020).

Frequently asked questions about Vaxcyte

Where is Vaxcyte headquartered?

Vaxcyte, Inc. is headquartered in San Carlos, California, United States.

What does Vaxcyte do?

Vaxcyte, Inc. is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).

Is Vaxcyte a public company?

Yes. Vaxcyte, Inc. trades on Nasdaq under the ticker PCVX.

When was Vaxcyte founded?

The earliest incorporation on record for Vaxcyte, Inc. is in 2013, according to public company registers.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Sources

Location data: GeoNames (geonames.org), CC BY 4.0.

Last updated 2026-09-23.